download BusinessFocus app
Golden Meditech Stem Cells回應Blue Ocean誤導性的附表 13D/A

Golden Meditech Stem Cells回應Blue Ocean誤導性的附表 13D/A

Market Information PR Newswire
By PR Newswire on 30 May 2022
PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

香港2022年5月30日 /美通社/ -- Golden Meditech Stem Cells (BVI) Company Limited(公司)謹就 Blue Ocean Structure Investment Company Ltd.(Blue Ocean」)於2022 年 5 月 27 日提交誤導性的附表 13D/A作出回應。

Blue Ocean 未能在其附表 13D/A 中提及維爾京群島高等法院的東加勒比最高法院(「法院」)將於 2022 年 6 月 16 日就該法院發佈的禁制令(「命令」)擧行進一步聆訊,也未提及該令是單方面授予的(即法庭尚未聽取公司的任何辯詞),並且公司有權在進一步聆訊當中尋求更改命令的條款。

公司將强烈反對Blue Ocean要求長期繼續執行該令。

【了解更多最快最新的財經、商業及創科資訊】

👉🏻 追蹤 WhatsApp 頻道 BusinessFocus

👉🏻 下載 BusinessFocus APP

👉🏻 立即Follow Instagram businessfocus.io

最新 金融投資熱話專頁 MarketFocus